Checked Jun 15, 2026
Does Medicare cover Ozempic and Wegovy? GLP-1 cost on Medicare in 2026
Medicare Part D does not cover any GLP-1 for weight loss, under a 2003 statute. It does cover Ozempic and Mounjaro for type 2 diabetes, and Wegovy for cardiovascular risk, at a $25 to $200 monthly copay. From July 1, 2026, the Medicare GLP-1 Bridge furnishes Wegovy, Zepbound and Foundayo at a flat $50 a month for qualifying Part D members. With no coverage at all, the cash floor is $178 a month.
Medicare covers a GLP-1 only when the prescription matches a covered medical condition. Ozempic and Mounjaro are covered for type 2 diabetes at a $25 to $100 copay. Wegovy is covered for cardiovascular risk at $50 to $200. For weight loss alone, Medicare covers nothing today, but from July 1, 2026 the Medicare GLP-1 Bridge sets a flat $50 a month for qualifying members. With no coverage, the cash floor is $178 a month.
- Diabetes: covered. Part D covers Ozempic and Mounjaro for type 2 diabetes at a $25 to $100 monthly copay. The most accessible Medicare GLP-1 path.
- Cardiovascular risk: covered. Part D covers Wegovy for established cardiovascular disease (since March 2024) at a $50 to $200 copay. Zepbound is covered for sleep apnea on the same copay range (since December 2024).
- Weight loss alone: not covered, until July 1, 2026. A 2003 statute excludes weight-loss drugs from Part D.
- Medicare GLP-1 Bridge: $50 a month flat. Wegovy, Zepbound or Foundayo for qualifying Part D members, July 1, 2026 through December 31, 2027.
- No coverage at all: $178 a month. Compounded semaglutide, the same active ingredient as Wegovy, billed month-to-month. The brand floor is the $149 oral Wegovy pill.
- The Bridge ends in 2027. It is a demonstration, not a permanent benefit. Treat the $50 price as a window, not a guarantee.
What Medicare covers, by indication
The single rule that governs every Medicare GLP-1 decision: Part D pays for the drug only when it is prescribed for a covered medical condition, not for weight loss by itself. A 2003 federal statute, the Medicare Modernization Act, specifically excludes drugs used for weight loss from Part D. That exclusion is why two people on the same medication can pay a $40 copay or the full cash price depending only on their diagnosis.
| Your situation | Covered drug | Cost / mo | What unlocks it |
|---|---|---|---|
| Type 2 diabetes | Ozempic, Mounjaro | $25 to $100 copay | A type 2 diabetes diagnosis on a Part D formulary |
| Established cardiovascular disease | Wegovy | $50 to $200 copay | Post-heart-event diagnosis, BMI 27 or higher |
| Moderate-to-severe sleep apnea | Zepbound | $50 to $200 copay | An OSA diagnosis with BMI 30 or higher |
| Weight loss, from July 1, 2026 | Wegovy, Zepbound, Foundayo | $50 flat (Bridge) | CMS clinical criteria, prior authorization |
| Weight loss, before July 1, 2026 | None on Medicare | $178 cash floor | Compounded semaglutide, paid out of pocket |
Copay ranges are typical Part D out-of-pocket figures and vary by plan and coverage phase. Cash prices are checked every Monday against each program's published pricing and logged on the Price Index. We do not create accounts or make purchases to verify them.
How Medicare Part D pays for a GLP-1
Part D is the prescription-drug part of Medicare, run by private plans under federal rules. Each plan publishes a formulary the list of drugs the plan will pay for, with the tier and copay for each and a set of coverage rules. For a GLP-1, the plan checks two things: is the drug on the formulary, and does your diagnosis match a covered indication. If both are true, you pay the tier copay. If the prescription is coded for weight loss with no covered condition behind it, the plan denies it under the 2003 exclusion.
The Inflation Reduction Act capped Part D out-of-pocket spending at $2,000 a year as of 2025, so a covered GLP-1 copay stops accumulating once you reach that ceiling. That cap matters most for the diabetes and cardiovascular paths, where the drug runs through the normal Part D benefit. The Medicare GLP-1 Bridge below sits outside Part D, so it works differently.
The Medicare GLP-1 Bridge: $50 a month from July 1, 2026
The biggest change to Medicare GLP-1 access is the Medicare GLP-1 Bridge, a CMS demonstration that runs from July 1, 2026 through December 31, 2027. It furnishes Wegovy, Zepbound and Foundayo at a flat $50 a month for Part D beneficiaries who meet the clinical criteria, for weight-management prescriptions only. It is the first time Medicare has paid for a GLP-1 prescribed for weight loss itself.
You qualify for the Bridge if you are a Part D beneficiary and you meet one of these thresholds:
- A BMI of 35 or higher, or
- A BMI of 30 or higher with heart failure, uncontrolled hypertension or chronic kidney disease, or
- A BMI of 27 or higher with pre-diabetes or a prior heart event.
Prior authorization is required. The Bridge operates outside the Part D benefit, which has two effects on your cost: no Part D deductible applies to it, and the $50 you pay does not count toward your $2,000 out-of-pocket cap. If you qualify, $50 a month beats every cash program we track. The full breakdown of what CMS published and what to do before July 1 is on our hub for adults 65 and older and in the GLP-1 coupons and savings guide.
What it costs with no Medicare coverage
If you want a GLP-1 for weight loss before July 1, 2026, or you do not meet the Bridge criteria, Medicare pays nothing and you are in the cash market. The floor there is $178 a month for compounded semaglutide through Mochi, the same active ingredient as Wegovy, prepared by a licensed pharmacy and billed month-to-month with no lock-in. The cheapest brand-name route is the $149 oral Wegovy pill at the starter dose through NovoCare, though the price rises at maintenance doses.
For fixed-income retirees, the cash bill is the hard part. Three pathways can lower it: NovoCare and LillyDirect patient-assistance programs, state senior pharmaceutical assistance such as New York EPIC, New Jersey PAAD and Pennsylvania PACE, and 340B clinic access if you live near a federally qualified health center. The full cash picture and every path is in the GLP-1 cost guide.
How to get a covered indication coded correctly
Most general telehealth programs do not know how to code a Medicare prescription for the cardiovascular or sleep-apnea indication, so the script comes back denied. The fix is a prescriber who writes it for the covered condition with the right documentation. If you have had a heart event, the prescription should be coded for cardiovascular risk reduction, not weight loss. If you have a sleep-apnea diagnosis, the documentation should reference the sleep study. Our prior-authorization letter templates for the cardiovascular indication, sleep apnea and type 2 diabetes carry the codes and trial citations each one needs.
For the broader coverage picture, including denial reasons and the four appeal pathways, see the GLP-1 insurance guide. To check whether a specific plan covers a specific drug, use the sourced payer coverage pages.
Programs that handle Medicare correctly
Three programs on our chart write Medicare prescriptions for the covered indications and handle the polypharmacy concerns common in senior care. The deeper guidance on dose strategy, muscle protection and patient assistance for adults 65 and older lives on the senior hub.
What to do next
If you have type 2 diabetes, ask your prescriber about Ozempic or Mounjaro on your Part D formulary, the cheapest covered path. If you have had a heart event or have sleep apnea, get the prescription coded for that indication using the PA templates above. If you want a GLP-1 for weight loss, mark July 1, 2026 and check whether you meet the Bridge criteria for the $50 flat price. If none of those fit, compare the cash programs on the GLP Chart and read the full cost guide.
Medicare GLP-1 cost FAQ
Does Medicare cover Ozempic?
Yes, for type 2 diabetes. Medicare Part D plans cover Ozempic and Mounjaro on formulary for patients with a type 2 diabetes diagnosis, at a copay that usually runs $25 to $100 a month depending on the plan and the coverage phase. Medicare does not cover Ozempic for weight loss, because a 2003 statute excludes weight-loss drugs from Part D.
Does Medicare cover Wegovy for weight loss?
Not for weight loss alone, until July 1, 2026. Today Medicare Part D covers Wegovy only for cardiovascular risk reduction in patients with established heart disease, at a $50 to $200 monthly copay. From July 1, 2026, the Medicare GLP-1 Bridge adds a weight-management path: a flat $50 a month for qualifying Part D beneficiaries who meet the clinical criteria.
What is the Medicare GLP-1 Bridge?
It is a CMS demonstration that runs from July 1, 2026 through December 31, 2027. It furnishes Wegovy, Zepbound and Foundayo at a flat $50 a month to Part D beneficiaries who meet CMS clinical criteria, for weight-management prescriptions only. It operates outside the Part D benefit, so no deductible applies and the $50 does not count toward your out-of-pocket total.
Who qualifies for the $50 Medicare GLP-1 Bridge?
Part D beneficiaries who meet the CMS clinical criteria: a BMI of 35 or higher, or a BMI of 30 or higher with heart failure, uncontrolled hypertension or chronic kidney disease, or a BMI of 27 or higher with pre-diabetes or a prior heart event. Prior authorization is required, and it covers weight-management prescriptions only.
How much does a GLP-1 cost on Medicare without an indication?
Until the Bridge starts on July 1, 2026, a Medicare beneficiary with no qualifying indication pays cash. The cheapest cash path is compounded semaglutide at $178 a month through Mochi, the same active ingredient as Wegovy, billed month-to-month. The cheapest brand-name route is the oral Wegovy pill at $149 a month at the starter dose through NovoCare.
Does Medicare cover Zepbound?
Only for moderate-to-severe obstructive sleep apnea, a path that opened in December 2024, at a $50 to $200 monthly copay. Medicare does not cover Zepbound for weight loss today. From July 1, 2026, the Medicare GLP-1 Bridge covers Zepbound at a flat $50 a month for qualifying weight-management patients.
Does Medicare cover Mounjaro?
Yes, for type 2 diabetes. Medicare Part D plans cover Mounjaro and Ozempic on formulary for patients with a type 2 diabetes diagnosis, at a copay that usually runs $25 to $100 a month. Mounjaro is the diabetes brand of tirzepatide; Zepbound is the weight-loss brand of the same molecule and follows the weight-loss rules above.
What is the cheapest way for a senior to get a GLP-1?
If you qualify for the Medicare GLP-1 Bridge from July 1, 2026, the flat $50 a month beats every cash program. If you have type 2 diabetes, the standard Part D copay on Ozempic or Mounjaro is usually the cheapest path. Without any coverage, compounded semaglutide starts at $178 a month, and state senior pharmaceutical assistance programs such as New York EPIC, New Jersey PAAD and Pennsylvania PACE can lower the bill further.
Will Medicare ever cover GLP-1 for weight loss permanently?
The Medicare GLP-1 Bridge is a demonstration scheduled to end on December 31, 2027. Permanent coverage would require either Congress repealing the 2003 weight-loss exclusion or CMS extending the demonstration. Neither is settled. Treat the $50 Bridge price as a window that is open from July 1, 2026 through the end of 2027, not a permanent benefit.
